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In Brief
Chauhan et al. provide insight into how
intrinsic apoptosis can be connected to
inflammation. In macrophages,
mitochondrial apoptosis results in IAP
depletion, which triggers caspase-8
activation. In this setting, caspase-8 is the
main protease that matures the central
pro-inflammatory cytokine IL-1b, while
the NLRP3 inflammasome only plays a
subordinate role.
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IL-1b is a cytokine of pivotal importance to the
orchestration of inflammatory responses. Synthe-
sized as an inactive pro-cytokine, IL-1b requires
proteolytic maturation to gain biological activity.
Here, we identify intrinsic apoptosis as a non-canon-
ical trigger of IL-1b maturation. Guided by the dis-
covery of the immunomodulatory activity of viopro-
lides, cyclic peptides isolated from myxobacteria,
we observe IL-1bmaturation independent of canon-
ical inflammasome pathways, yet dependent on
intrinsic apoptosis. Mechanistically, vioprolides
inhibit MCL-1 and BCL2, which in turn triggers
BAX/BAK-dependent mitochondrial outer mem-
brane permeabilization (MOMP). Induction of
MOMP results in the release of pro-apoptotic fac-
tors initiating intrinsic apoptosis, as well as the
depletion of IAPs (inhibitors of apoptosis proteins).
IAP depletion, in turn, operates upstream of ripopto-
some complex formation, subsequently resulting in
caspase-8-dependent IL-1b maturation. These re-
sults establish the ripoptosome/caspase-8 complex
as a pro-inflammatory checkpoint that senses the
perturbation of mitochondrial integrity.
INTRODUCTION
Interleukin 1b (IL-1b) is a pleiotropic cytokine, which is crucial
to orchestrating host defense against a variety of pathogens.2354 Cell Reports 25, 2354–2368, November 27, 2018 ª 2018 The A
This is an open access article under the CC BY-NC-ND license (http://At the same time, IL-1b has been shown to participate in the
pathogenesis of many sterile inflammatory conditions (Dinar-
ello, 2011). IL-1b is synthesized as a cytosolic precursor pro-
tein that requires cleavage for biological activity. Upon matura-
tion, it is released into the extracellular space to exert its
activity, a process that typically relies on the activation of
macromolecular complexes known as inflammasomes (Broz
and Dixit, 2016). Inflammasomes are high-molecular-weight
cytoplasmic complexes formed in response to various microbi-
al molecular patterns or perturbations of cellular homeostasis.
In general, inflammasomes consist of a sensor protein (e.g., an
NLR protein), the adaptor protein ASC (gene name PYCARD),
and the protease caspase-1. Upon activation, the sensor pro-
tein seeds the prion-like multimerization of the adaptor ASC
through homotypic pyrin domain (PYD) interactions, which
induce the formation of large ASC filament structures. This in
turn results in the recruitment of caspase-1, which itself is
then activated by proximity-induced auto-cleavage. Active
caspase-1 catalyzes the proteolytic maturation of IL-1b and
its IL-1 family member IL-18 (Broz and Dixit, 2016). In addition
to its cytokine substrates, caspase-1 cleaves the cell death
effector molecule gasdermin D (GSDMD), which results in the
formation of a pore in the plasma membrane, triggering a
form of cell death known as pyroptosis (Kayagaki et al.,
2015; Liu et al., 2016; Shi et al., 2015). Mature IL-1b can gain
access to the extracellular space in the context of pyroptosis
or other types of cell death (Gaidt and Hornung, 2018). In addi-
tion, it can be released through GSDMD pores that form at the
plasma membrane preceding cell disintegration (Evavold et al.,
2018). However, under certain conditions, IL-1b can also be
released from living cells, independently of GSDMD or pyrop-
tosis (Conos et al., 2016; Gaidt et al., 2016).uthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Among all inflammasome sensor proteins, NLRP3 is the most
studied to date because of its critical role in sterile inflammatory
diseases. These include rare,monogenetic autoinflammatorydis-
eases, in which gain-of-function mutations within NLRP3 cause
autoactivation of the NLRP3 inflammasome, as well as common,
stimulus-dependent modes of NLRP3 activation, as observed in
gout, atherosclerosis, or Alzheimer’s disease (Dinarello, 2011;
Masters et al., 2009). Inflammasome-dependent IL-1bmaturation
is a two-step process, in which signal 1 serves as the priming
signal, which is required to induce pro-IL-1b expression, and
signal 2 constitutes the stimulus that activates the inflammasome
sensor itself. In the case of the NLRP3 inflammasome, signal 1
additionally serves to facilitateNLRP3activation at transcriptional
and post-transcriptional levels (Bauernfeind et al., 2009; Juliana
et al., 2012). While the exact mechanism of NLRP3 activation re-
mains unclear, a link has been established between most of the
currently known NLRP3 stimuli and the lowering of cytoplasmic
K+ levels. Moreover, decreases in intracellular K+ are known to
be sufficient for NLRP3 activation (Franchi et al., 2007; Pe´trilli
et al., 2007). Given the fact that K+ efflux readily occurs along its
electrochemical gradient when the integrity of plasmamembrane
is breached, NLRP3 can be considered a sensor of membrane
perturbation (Gaidt and Hornung, 2018). In addition, it has been
proposed that lossofmitochondrial integrity leading to the release
of mitochondrial damage-associated molecular patterns
(DAMPs) can trigger NLRP3 inflammasome activation (Iyer
et al., 2013; Shimada et al., 2012). These studies have demon-
strated evidence for amechanism inwhichmitochondrial DAMPs
are released downstream of K+ efflux and upstream of NLRP3
activation. However, this concept was challenged by genetic
models in which the inhibition of mitochondrial DAMP release
had no effect on canonical NLRP3 activation (Allam et al., 2014).
Apart from caspase-1, other enzymes have been shown to be
capable of IL-1b maturation. This includes enzymes that can
cleave IL-1b in the extracellular space, such as neutrophil-
derived proteases, or caspase-8, which can process IL-1b in a
cell-intrinsic fashion like caspase-1(Afonina et al., 2015; Maelfait
et al., 2008). To date, several pathways leading to caspase-8-
mediated IL-1b maturation have been described. One such
pathway is the activation of caspase-8 in the context of ripopto-
some formation that leads to IL-1b cleavage (Lawlor et al., 2015;
Vince et al., 2012). The ripoptosome is a caspase-8-activating
signaling hub that is formed by receptor-interacting serine/thre-
onine-protein kinase 1 (RIPK1) under certain conditions, where
it is able to recruit Fas-associated death domain (FADD) and
subsequently caspase-8. Here, a key checkpoint function has
been ascribed to the E3 ubiquitin ligases cellular inhibitor of
apoptosis 1 (cIAP1), cIAP2, and, under certain conditions,
XIAP (referred to in the following as IAPs). In the context of
Toll-like receptor- (TLR-) and tumor necrosis factor receptor
1- (TNFR1-) dependent signaling cascades, IAPs ubiquitinate,
among other targets, RIPK1, allowing it to engage in nuclear fac-
tor kB (NF-kB) activation and preventing it from forming a ripop-
tosome complex (Feoktistova et al., 2011; Tenev et al., 2011).
However, in the absence of IAPs, de-ubiquitinated RIPK1 initi-
ates the formation of a ripoptosome complex, which can act
independently of an additional upstream signal. Thus, treating
cells with compounds that deplete IAPs leads to the formationof a caspase-8-activating ripoptosome complex. Using this
model system, it has been shown that TLR-primedmacrophages
cleave IL-1b in a caspase-8-dependent manner (Lawlor et al.,
2015; Vince et al., 2012). However, a physiological role for this
type of IL-1b maturation has not been identified to date.
RESULTS
The Vioprolide Family of Cyclic Peptolides Induces IL-1b
Release
To identify thus-far uncharacterized immunostimulatory com-
pounds, a library of 259 natural small molecules purified from
myxobacteria was screened for its capacity to induce IL-1b
release from a murine macrophage cell line (Surup et al., 2018).
This library was chosen because myxobacteria are known for
their structurally diverse secondary metabolites that have only
scarcely been explored for their biological activity (Herrmann
et al., 2017). Our analysis identified vioprolide A (Vio A) as an
inducer of IL-1b release. Vio A belongs to a class of cyclic pep-
tolides, the vioprolides (Figure S1A), isolated from the myxobac-
terium Cystobacter violaceus (Schummer et al., 1996). While
vioprolides are known to have antifungal properties and
demonstrate cytotoxicity in eukaryotic cells (Schummer et al.,
1996; Weissman and M€uller, 2010), their mode of action re-
mains unknown, and a role in IL-1b activation has not been
reported to date (Bollati-Fogolin and M€uller, 2008). To test the
IL-1b-inducing capacity of Vio A in primary cells, we stimulated
primary murine BMDMs (bone marrow-derived macrophages)
(Figure 1A) and human PBMCs (peripheral blood mononuclear
cells) (Figure 1B) with Vio A, while nigericin and double-stranded
DNA (dsDNA) were included as controls to stimulate the NLRP3
or the absent in melanoma 2 (AIM2) inflammasome, respectively.
Vio A triggered IL-1b release in both cell populations in a dose-
dependent manner, but to a lesser extent than nigericin or
dsDNA. The other known members of the vioprolide family, vio-
prolides B, C, and D (Figure S1), also induced IL-1b release, with
Vio A and Vio B being the most potent activators (Figure 1C). Of
note, as observed for nigericin, vioprolide treatment also re-
sulted in lactate dehydrogenase (LDH) release, which is indica-
tive of a lytic form of cell death (Figure 1D). To determine whether
stimulation with vioprolides resulted in the proteolytic activation
of IL-1b in addition to its release, the cellular supernatants and
lysates of vioprolide-treated wild-type (WT) BMDMs were
probed for cleaved caspase-1 and IL-1b via immunoblotting. In
line with the positive control nigericin, vioprolides A, B, C, and
D induced the release of fully mature IL-1b (17 kDa) and cas-
pase-1 (20 kDa) into the cellular supernatant (Figure 1E). Thus,
our data demonstrate that vioprolides are a family of cyclic
peptides that are capable of inducing caspase-1 and IL-1b
activation.
Vioprolides Induce IL-1b Release and Cell Death via
NLRP3-Dependent and -Independent Mechanisms
To elucidate the pathway of vioprolide-mediated IL-1b matura-
tion and LDH release, we stimulated WT BMDMs and cells defi-
cient for the inflammasome components NLRP3, ASC, and cas-
pase-1/11 with Vio A and Vio B, as well as with nigericin and
dsDNA. In WT macrophages, stimulation with Vio A and Vio BCell Reports 25, 2354–2368, November 27, 2018 2355
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Figure 1. The Vioprolide Family of Cyclic Peptolides Induces IL-1b Release
(A) Wild-type (WT) BMDMswere primed with LPS (200 ng/mL) for 4 hr and stimulated with indicated concentrations of Vio A (in mM), nigericin, and dsDNA for 8 hr.
(B) Human PBMCs primed with LPS (50 pg/mL) for 4 hr and followed by stimulation with different concentrations of Vio A (in mM) and nigericin for 6 hr.
(C–E) LPS-primedWT BMDMs treated with nigericin and 20 mMof Vio A, B, C, and D for 8 hr. Samples were analyzed for (C) IL-1b release via ELISA and tested for
(D) LDH activity in cellular supernatant and (E) immunoblot.
Data are depicted as mean + SEM of (A) four, (B) two (C and D) three or one representative blot of (E) three independent experiments. Sup, supernatant;
Lys, lysate.
See also Figure S1.resulted in the dose-dependent release of cleaved IL-1b (Figures
2A and S2A), as well as LDH (Figures 2B and S2E). While viopro-
lide-mediated IL-1bmaturation and LDH release were largely un-
affected by NLRP3, ASC, or caspase-1/11 deficiency (Figures
2A, 2B, S2A–S2H, and S3A–S3D), caspase-1 maturation was
fully abrogated in NLRP3- and ASC-deficient BMDMs (Figures
S3B and S3C). The control stimuli nigericin and dsDNA acted
as expected in regard to their NLRP3, ASC, and/or caspase-1
dependence (Figure 2A). It should be noted that lytic cell death
and its surrogate marker LDH release upon NLRP3 stimulation
is caspase-1 dependent at early time points, but executed by
caspase-1-independent mechanisms in Casp1/ cells at later
time points (Figures S3E–S3G) (Antonopoulos et al., 2015).
Moreover, we also studied the role of the pyroptosis effector
molecule GSDMD, which has been shown to mediate cell death
and IL-1b release downstream of inflammasome activation
(Kayagaki et al., 2015; Shi et al., 2015). As expected, BMDMs
deficient in GSDMD showed a marked delay in IL-1b and LDH
release after NLRP3 inflammasome stimulation (Figures 2C
and 2D), yet Vio A-dependent LDH release was unaffected by2356 Cell Reports 25, 2354–2368, November 27, 2018GSDMD deficiency. Furthermore, while Vio A stimulation re-
sulted in IL-1b and LDH release by different TLR ligands,
including lipopolysaccharide (LPS) (Figure 2E), Vio A-induced
LDH release occurred even in the absence of any TLR ligands
(Figure 2F). Thus, our data demonstrate that vioprolides activate
both NLRP3 inflammasome-dependent and -independent path-
ways. However, the maturation and release of IL-1b and the in-
duction of cell death are largely independent of inflammasome
components and GSDMD.
Vio A Triggers BAX- and BAK-Dependent Intrinsic
Apoptosis, Resulting in IL-1b and LDH Release
At this point, our results raised the following questions: which
caspase-1-independent cell death program is triggered by vio-
prolides, and how do vioprolides trigger the maturation and
release of IL-1b? At the same time, what mechanism results in
vioprolide-dependent activation of the NLRP3 inflammasome?
To address the first question, we went on to further characterize
the cell death induced by vioprolide exposure. To this end, we
performed a DNA laddering assay, which revealed that Vio A
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Figure 2. Vioprolides Induce IL-1b Release
and Cell Death via NLRP3-Dependent and
-Independent Mechanisms
(A and B) BMDM samples deficient in various in-
flammasome proteins were primed with LPS
(200 ng/mL) for 4 hr and followed by 20 mMof Vio A
and Vio B. Nigericin and dsDNA were used as
controls. Cellular supernatants were assessed by
(A) IL-1b ELISA and (B) LDH release after 8 hr.
(C and D) IL-1b (C) and LDH measurement (D) in
the cellular supernatants of LPS-primed WT and
Gsdmd/ BMDMs stimulated with nigericin and
Vio A for the indicated time points.
(E and F) WT and Casp1/11/ BMDMs were
primed with or without different TLR ligands for
4 hr (LPS: 200 ng/mL, Pam3CSK4: 2.5 mg/mL,
R848: 2 mg/mL). Priming was followed by stimu-
lation of Vio A and nigericin for 8 hr; cellular su-
pernatants were analyzed for (E) IL-1b via ELISA
and (F) LDH activity.
Error bars represent mean + SEM of (A and B) four,
(C and D) two, and (E and F) three independent
experiments. *p < 0.05, **p < 0.01, ns, not signifi-
cant. Either individual genotypes were compared
to the WT genotype or individual conditions were
compared to the respective unstimulated control.
See also Figures S2 and S3.stimulation induced DNA fragmentation, a hallmark of apoptosis
(Figures 3A and S4A). Although LDH release is not considered
characteristic for apoptotic cell death, it has been shown that
apoptotic stimuli can also result in LDH release due to secondary
necrosis at late time points (England et al., 2014). Therefore, to
differentiate between apoptotic and lytic cell death, we per-
formed a time course for caspase-3 activation and LDH release
using the protein kinase inhibitor staurosporine (STS) as an
apoptosis-inducing control (England et al., 2014). Here, differ-
ences in caspase-3 activation and LDH release could be
observed. Whereas Vio A treatment resulted in early proteolyticCell Reportsprocessing of caspase-3 (120 min) (Fig-
ure 3B), LDH release took place at a later
time point (6 hr) (Figure 3C). Furthermore,
we also observed processing of the initi-
ator caspase-9 within 60 min of Vio A
treatment, which was in line with early
caspase-3 activation (Figure 3B). As ex-
pected, STS induced caspase-9 and
caspase-3 activation, as well as DNA
laddering (Figures 3A and 3B). Moreover,
as previously shown, STS induced LDH
release at later time points (6 and 10 hr)
(Figures 3C and S6D) (England et al.,
2014; Shimada et al., 2012). Caspase-9
represents the initiator caspase involved
in intrinsic apoptosis, which is activated
by cytosolic cytochrome c released from
mitochondria after mitochondrial outer
membrane permeabilization (MOMP) (El-
more, 2007). To study its potential involve-ment, WT BMDMs were stimulated with Vio A, and cytosolic frac-
tions were isolated at various time points. Cytosolic cytochrome c
was detected upon exposure to Vio A within minutes after treat-
ment and was followed by the activation of caspase-9 and
caspase-3 (Figure 3B; data not shown), strongly suggesting that
Vio A treatment leads to the induction of MOMP.
MOMP is controlled by anti-apoptotic B cell lymphoma 2
(BCL2) protein family members that inhibit the oligomerization
of pro-apoptotic members BAX and BAK, which in turn induces
the release of pro-apoptotic factors such as cytochrome c (Youle
and Strasser, 2008). Thus, to investigate the role of the BCL225, 2354–2368, November 27, 2018 2357
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Figure 3. Vio A Triggers BAX- and BAK-Dependent Intrinsic Apoptosis, Resulting in IL-1b and LDH Release
(A) WT BMDMs were stimulated with Vio A and B for 6 hr and analyzed for DNA laddering. STS and LPS + nigericin were used as positive and negative controls,
respectively. These data are representative of three independent experiments.
(B and C) WT BMDMs were treated with Vio A and STS, and samples were probed for (B) immunoblot and (C) LDH activity at indicated time points. Data are
depicted as (B) one representative blot or (C) means + SEMs of three independent experiments.
(D–F) LPS primed WT and Bax//Bak1/ BMDMs treated with Vio A and STS for the indicated time points. Samples were taken for (D) immunoblot at the
indicated time points. In addition, cellular supernatants were analyzed for (E) LDH activity and (F) IL-1b via ELISA. Data are shown as (D) one representative blot or
(E and F) mean + SEM of three independent experiments. *Non-specific cross-reactivity of the antibody. *p < 0.05, **p < 0.01, ns, not significant.
See also Figure S4.protein family in Vio A-induced cell death, we used BAX- and
BAK-deficient BMDMs. In comparison to WT cells, Bax//
Bak1/ cells demonstrated a marked delay in caspase-9 and
caspase-3 activation after Vio A treatment (Figure 3D). Moreover,2358 Cell Reports 25, 2354–2368, November 27, 2018the deficiency of BAX and BAK both significantly delayed and
reduced Vio A-induced LDH and IL-1b release (Figures 3E and
3F). However, compared to WT cells, Bax//Bak1/ cells dis-
played an initial reduction in LDH release 4 hr after STS treatment
but not at later time points. Of note, in line with previous work, the
deficiency of BAX and BAK had no impact on STS or nigericin-
induced IL-1b maturation (Allam et al., 2014) (Figures 3F and
S4B). Analogous results were observed when we studiedmacro-
phages that ectopically overexpress Bcl2 (OXP-BCL2) (Knittel
et al., 2016). Compared to WT cells, OXP-BCL2 cells showed a
marked decrease in LDH and IL-1b release when treated with
vioprolides, while IL-1b and LDH release following nigericin stim-
ulation remained unaffected (Figures S4C and S4D). This was
paralleled by a strong decrease in vioprolide-mediated intrinsic
apoptosis induction (caspase-9 and caspase-3 activation) in
OXP-BCL2 cells (Figure S4D). As an additional control, we
used the second mitochondria-derived activator of caspase
(Smac) mimetic birinapant, which can trigger largely inflamma-
some-independent IL-1b maturation by IAP depletion (Lawlor
et al., 2015; Vince et al., 2012) (Figures S4E and S4F). As ex-
pected, birinapant treatment readily induced LDH and IL-1b
release, yet this response was only slightly affected by the over-
expression of Bcl2. In summary, these results demonstrate that
Vio A induces BAX- and BAK-dependent intrinsic apoptosis,
leading to both IL-1b maturation and LDH release.
Vioprolides Act as Translational Inhibitors
Next, we wanted to explore how vioprolides trigger BAX/BAK
activation upstream of MOMP. Pro-apoptotic Bcl-2 homology
(BH) domain 3-only proteins induce MOMP by directly activating
pro-apoptotic BAX/BAK and/or by antagonizing anti-apoptotic
BCL2 proteins (Youle and Strasser, 2008). In macrophages, it
has been shown that the depletion of the anti-apoptotic protein
myeloid cell leukemia sequence 1 (MCL-1) plays a pivotal role in
intrinsic apoptosis induction. However, MCL-1 depletion alone
is not sufficient, and at least one additional signal is required to
trigger MOMP in macrophages (Dzhagalov et al., 2007). Because
intrinsic apoptosis was observed with Vio A treatment, WT
BMDMswere tested for MCL-1 expression at the mRNA and pro-
tein levels after Vio A treatment (Figure 4A). MCL-1 is a short-lived
protein that requires constant synthesis to maintain a stable
expression level. Consequently, cycloheximide (CHX) and other
translational inhibitors quickly decrease MCL-1 levels (Adams
and Cooper, 2007). Although CHX treatment did not change
MCL-1 transcript levels, Vio A treatment led to a marked increase
in MCL-1 mRNA. Nonetheless, both CHX and Vio A treatment re-
sulted in a substantial decrease in MCL-1 protein (Figure 4A),
indicating that Vio A induces MCL-1 protein degradation at the
post-transcriptional level. To investigate whether Vio A acts as a
translational inhibitor in vitro, we used a eukaryotic cell-free trans-
lational system with mRNA encoding human hemoglobin subunit
beta (HBB) (Matheisl et al., 2015). Cell-free translational extracts
were incubated with Vio A and CHX for 40 min (Figure 4B) or
DMSOas a control. In linewith its ability to decreaseMCL-1 levels
in BMDMs, Vio A inhibited the translation of HBB in the cell-free
system. The half-maximum inhibitory concentration (IC50) was
112 nM for Vio A, while CHX displayed an IC50 of 945 nM.
Having established intrinsic apoptosis as the upstream acti-
vating pathway of Vio A-dependent IL-1b and LDH release, we
investigated whether intrinsic apoptosis in general could induce
these effects. To this end, LPS-primed BMDMs were cultured in
the presence and absence of CHX to deplete MCL-1 and treatedwith the BCL2/BCL-XL (B cell lymphoma-extra large) inhibitor
ABT-737 (Oltersdorf et al., 2005) (Figure 4C). As expected,
ABT-737 treatment alone was not sufficient for the induction of
intrinsic apoptosis, and no activation of caspase-3 or caspase-
9 was observed. Thus, ABT-737 treatment alone also did not
induce the maturation of IL-1b or caspase-1. However, when
combined with CHX to induce MCL-1 depletion, ABT-737 could
trigger intrinsic apoptosis, as well as the maturation of IL-1b and
caspase-1. Conversely, in line with our previous data, CHX treat-
ment was not required for Vio A-dependent IL-1bmaturation and
caspase-1 activation (Figure 4C). Similar to Vio A, CHX + ABT-
737-induced IL-1b was largely independent of NLRP3 (Fig-
ure S5A). Furthermore, the proteasomal inhibitor MG-132 could
slightly restoreMCL-1 levels in Vio A-treated cells, which is in line
with previous reports of proteasomal degradation of MCL-1
(Adams and Cooper, 2007). Stabilizing MCL-1 levels via
MG-132 delayed the kinetics of Vio A-dependent apoptosis
and IL-1b maturation (Figure S5B). These data indicate that
vioprolides act as translational inhibitors, thus decreasing the
protein levels of the crucial pro-survival BCL2 family member
MCL-1. At the same time, vioprolides appear to confer an addi-
tional pro-apoptotic signal upstream of BAX/BAK. The combina-
tion of both functionalities then triggers MOMP in macrophages
(Figure 4D). Accordingly, these events can be mimicked by the
combination of a translational inhibitor (CHX) that depletes
MCL-1 and a BCL2/BCL-XL antagonizing compound.
Vioprolides Inhibit Pro-survival BCL2
To identify the second trigger activated by vioprolides, we used
the previously described mito-priming method (Lopez et al.,
2016). In brief, in this method, seminal vesicle epithelial cells
(SVECs) are rendered ‘‘addicted’’ to specific BCL2 proteins via
the constitutive co-expression of an anti-apoptotic and a pro-
apoptotic protein. This configuration makes them dependent
on the specific BCL2 protein for their survival. We treated
BCL2, BCL-XL, and MCL-1 mito-primed cell lines with viopro-
lides and tracked their survival in a time course experiment via
a SYTOX green exclusion assay; BCL2-, BCL-XL-, and MCL-1-
specific inhibitors served as specificity controls, whereas the
combined treatment of ABT-737 + actinomycin D was used as
a pro-apoptotic stimulus that was active across all three cell
lines. Vioprolides specifically resulted in the death of BCL2-
dependent cells, while BCL-XL-dependent cells were completely
unaffected by vioprolide treatment (Figures 5A, 5B, S5C, S5D,
and S5F). Moreover, vioprolide treatment also resulted in the
death of MCL-1-dependent cells (Figures 5C, S5E, and S5F).
Taken together with our data on BCL2 overexpression (Figures
S4C and S4D) and MCL-1 depletion (Figures 4A and 4C), these
findings confirm that vioprolides inhibit MCL-1 and BCL2,
providing two distinct triggers to initiate BAX/BAK-dependent
MOMP (Figure S5G).
Caspase-8 Is the Main Protease Catalyzing IL-1b
Maturation during Intrinsic Apoptosis
While our results thus far strongly suggested that intrinsic
apoptotic machinery mediates the cleavage of IL-1b indepen-
dently of caspase-1, the respective protease remained elusive.
In addition to cytochrome c release, MOMP triggers the releaseCell Reports 25, 2354–2368, November 27, 2018 2359
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Figure 4. Vioprolides Act as Translational Inhibitors
(A) WT BMDMs treated with or without LPS for 4 hr and followed by stimulation with Vio A and cycloheximide (CHX) for the indicated time points. Samples were
analyzed for Mcl-1 expression at mRNA level (top) and protein level (bottom).
(B) Immunoblot of cell-free translational assay for human HBB mRNA in the presence and absence of the indicated concentrations of Vio A and CHX for 40 min.
DMSO control was used for maximum translation, while translational extract without mRNA was used as negative control and for background normalization.
For IC50 determination, curve fitting was performed with non-linear regression with log(inhibitor) versus normalized response parameter logistic. Data are
mean + SEM or one representative blot of three independent experiments.
(C) WT BMDMswere primed with LPS for 4 hr and stimulated with nigericin, birinapant, Vio A, and ABT-737 in the presence and absence of CHX. CHXwas added
in the last 45 min of priming. Samples were taken after 8 hr for LDH release (top) and immunoblot (bottom).
(D) Schematic representation of Vio A-induced MOMP.
(A and C) One representative blot of three independent experiment. Error bars represent mean + SEM of three independent experiments. *p < 0.05, **p < 0.01, ns,
not significant.
See also Figure S5.of other pro-apoptotic factors such as SMAC/DIABLO (direct in-
hibitor of apoptosis-binding protein with low isoelectric point) and
mitochondrial serine protease HTRA2 (HtrA2), which antagonize
IAP proteins (Elmore, 2007). In the context of MOMP, it is well
established that IAP depletion can amplify apoptotic signaling
cascades. However, using synthetic compounds, it has also
been shown that depleting IAPs can trigger ripoptosome-depen-
dent caspase-8 activation, leading to direct IL-1b maturation
(Lawlor et al., 2015; Vince et al., 2012).Whether the latter pathway
is operational in the context of MOMP has not yet been ad-2360 Cell Reports 25, 2354–2368, November 27, 2018dressed. In the light of these considerations, we investigated
whether Vio A triggers the release of pro-apoptotic factors from
mitochondria that antagonize IAPs. To this end, unprimed WT
BMDMswere treatedwith Vio A, and cytosolic fractionswere iso-
lated at different time points. Cytochrome c was detected in the
cytosol within 15 min of Vio A treatment, and its levels increased
further with time (Figure 6A). In addition to cytochrome c, the pro-
apoptotic factor SMACwas also detected in the cytosolic fraction
2 hr after stimulation. Its release correlated with the depletion of
all three IAPs tested, predominantly cIAP2 (Figure 6A). Next, we
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Figure 5. BCL2 Inhibition Confers Second Trigger for BAX/BAK-Dependent MOMP
(A–C) BCL2- (A), BCL-XL- (B), andMCL-1- (C) dependent SVEC cells were treated with the indicated stimuli for the indicated time points. Cell death was analyzed
by SYTOX green+ cells/mm2 and normalized to the initial confluency of respective wells. Data are representative of three independent experiments.
See also Figure S5.probed for the activation of caspase-8 in the supernatants of Vio
A-treated samples, and depletion of all three IAPs correlated with
an increase in caspase-8 activation. Moreover, in line with the
aforementioned concept of IAP depletion and subsequent cas-
pase-8 activation downstream of MOMP, BAX/BAK deficiency
markedly delayed the depletion of IAPs and caspase-8 activation.
Of note, MCL-1 degradation was independent of BAX and BAK,
thus positioning it upstream of MOMP (Figure S6A). Similar ob-
servations were made in OXP-BCL2 macrophages. Overexpres-
sion of BCL2 prevented degradation of all three tested IAPs, and
a reduced activation of caspase-8 after vioprolide treatment was
observed (Figure S6B). As previously reported, STS treatment
also resulted in the activation of caspase-8 (Figure 6A) (Antono-
poulos et al., 2013). However, the mechanism of STS-dependent
caspase-8 activation differed from Vio A in that it occurred inde-
pendently of BAX and BAK, thereby excluding MOMP as the
driving force (Figure S6A).
To determine whether caspase-8 is directly involved in Vio A-
mediated IL-1b processing, we studied IL-1b maturation in
Casp8//Ripk3/ andRipk3/BMDMs. Because genetic defi-
ciency of caspase-8 alone is lethal inmice due to the engagement
of the necroptotic pathway, caspase-8 deficiency can only be
investigated in an Ripk3- or Mlkl-deficient background (Dillon
et al., 2014; Kaiser et al., 2011; Oberst et al., 2011). As expected,
treatment with the Smac mimetic birinapant resulted in mature
IL-1b and LDH release from WT cells, which was completely
dependent on ripoptosome-mediated caspase-8 activation (Fig-
ure 6B) (Lawlor et al., 2015). In contrast, nigericin could still induceIL-1b maturation in Casp8//Ripk3/ cells, although IL-1b and
LDH release were slightly reduced (Figure 6B). However, it should
be noted that deficiency in caspase-8 also leads to defects in
NF-kB signaling (Allam et al., 2014), which we could only partially
compensate for with higher doses of LPS (Figure S6C). In
contrast, Vio A-mediated IL-1b release was completely depen-
dent on caspase-8, and LDH release was substantially reduced
compared to WT cells. Because caspase-8 can initiate intrinsic
apoptosis via BH3-interacting domain death agonist (BID)
(Elmore, 2007), we additionally studied BID cleavage and the
activation of caspase-9 and caspase-3 after Vio A stimulation in
Casp8//Ripk3/ and Ripk3/ BMDMs (Figure 6C). However,
Casp8//Ripk3/ still showed activation of intrinsic apoptosis
after Vio A treatment, demonstrating that vioprolides induce
intrinsic apoptosis independently and thus upstream of cas-
pase-8 (Figures 3B and 6C). These results were also in line with
the fact that caspase-3 activation preceded the activation of cas-
pase-8 in Vio A-treated cells (Figure S6D). Because we had
observed IAP depletion before caspase-8 activation (Figure 6A),
we additionally determined levels of cIAP1, cIAP2, and XIAP in
Casp8//Ripk3/. Vio A treatment resulted in the depletion of
all three IAPs independently of caspase-8 (Figure 6C). In contrast,
the Smac mimetic birinapant induced the degradation of cIAP2
and XIAP in a caspase-8-dependent manner (Figure 6C). Of
note, treatment of CHX + ABT-737 and Vio A showed a similar
pattern of IL-1b and LDH release. However, the kinetics of
IL-1b and LDH release were faster for CHX + ABT-737 as
compared to Vio A (Figures S6E and S6F).Cell Reports 25, 2354–2368, November 27, 2018 2361
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Figure 6. Caspase-8 Is the Main Protease in IL-1b Maturation during Intrinsic Apoptosis
(A) Immunoblot of cytosolic fractions of unprimed WT BMDMs treated with Vio A for different time points. STS (4 hr) was used as a control for cytochrome
c release.
(B and C)WT,Casp8//Ripk3/ and Ripk3/BMDMs primed with 1000 ng/mL LPS for 4 hr followed by stimulation with nigericin, birinapant, and Vio A for 8 hr.
Samples were assessed for (B) LDH activity (top) and probed for (B and C) immunoblot.
(D) Schematic representation of Vio A and birinapant signaling pathway, in which the thick line represents strong signal, while the thin line represents weak signal.
Data are depicted as (A–C) one representative blot or (B) mean + SEM of two independent experiments. *Non-specific cross-reactivity of the antibody.
See also Figure S6.In summary, these results indicated that vioprolide-triggered
MOMP results in the release of pro-apoptotic factors, which in
turn deplete IAPs. This leads to the activation of caspase-8
that directly matures IL-1b. While birinapant-mediated cas-
pase-8 activation bypasses the need for MOMP induction, it still
requires MOMP to fully deplete IAPs, creating a feedback loop
for maximal caspase-8 activation (Figure 6D).
Intrinsic Apoptosis Results in Ripoptosome-Caspase-8-
Dependent and -Independent NLRP3-Caspase-1
Activation
The delay in intrinsic apoptosis also correlated with a delay in Vio
A-dependent caspase-1 activation, indicating that NLRP3-in-
flammasome activation in response to Vio A is secondary to2362 Cell Reports 25, 2354–2368, November 27, 2018intrinsic apoptosis (Figure 3D). Moreover, it has been shown
that Smac mimetics result in ripoptosome-caspase-8-mediated
NLRP3-inflammasome activation (Lawlor et al., 2015). Nonethe-
less, how caspase-8 activates NLRP3-caspase-1 in this context
remains unknown. To determine which signaling step of the
MOMP-ripoptosome-caspase-8 cascade triggers NLRP3, we
studied NLRP3 activation in Casp8//Ripk3/ and Ripk3/
macrophages (Figures 7A and 7B). Cells were primed with LPS
and stimulated with nigericin, Vio A, and birinapant in the pres-
ence or absence of MCC950, a specific NLRP3 inhibitor (Coll
et al., 2015). As expected, nigericin-mediated caspase-1 activa-
tion was completely abrogated in the presence of MCC950 in all
of the genotypes (Figures 7A and 7B) (Coll et al., 2015). In addi-
tion to IL-1b maturation, MCC950 inhibited LDH release after
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Figure 7. Intrinsic Apoptosis Results in Ripoptosome-Caspase-8-Dependent and -Independent NLRP3-Caspase-1 Activation
(A and B) Immunoblot of (A) WT and Casp8//Ripk3/ or (B) WT and Ripk3/ BMDMs primed with LPS (1,000 ng/mL) for 4 hr and stimulated with nigericin,
birinapant, and Vio A in the presence or absence of MCC950 (added in the last hour of priming).
(C) WT BMDMs were primed with LPS (200 ng/mL) for 4 hr, followed by the addition of indicated concentrations of K+ in the medium in the last 15 min of priming.
Samples were stimulated with nigericin, birinapant, and Vio A (20 mM) and analyzed by immunoblot after 8 hr.
(D and E) Primary human monocytes were primed with Pam3CSK4 for 4 hr and followed by stimulation of nigericin and Vio A in the absence and presence of
MCC950. MCC950 was added in the last hour of priming. After 6 hr, samples were analyzed for (D) immunoblot and (E) IL-1b and LDH release.
Data are representative of (A and B) two, (C and D) three and (E) four independent experiments/donors. *Non-specific cross-reactivity of the antibody.
See also Figure S7.nigericin treatment (Figures S7A and S7B). In line with previous
work (Lawlor et al., 2015), the Smac mimetic birinapant resulted
in NLRP3-dependent caspase-1 processing that occurred
downstream of ripoptosome/caspase-8-activation, and Ripk3
deficiency on its own led to reduced caspase-8 and caspase-1
activation. However, birinapant-mediated LDH release pro-
ceeded independently of NLRP3 (Figures S7A and S7B). Simi-larly, Vio A-dependent caspase-1 activation was fully NLRP3
dependent. While the majority of this inflammasome response
occurred downstream of ripoptosome/caspase-8, we also
observed a small-proportion caspase-8-independent NLRP3
activation (Figure 7A).
To further characterize the observed phenomenon of cas-
pase-8-dependent NLRP3 activation, we used a hyperkalemicCell Reports 25, 2354–2368, November 27, 2018 2363
extracellular buffer, which inhibits NLRP3 inflammasome activa-
tion in the context of membrane perturbation (Franchi et al.,
2007; Pe´trilli et al., 2007). In keeping with previously published
studies, elevated potassium levels inhibited caspase-1 matura-
tion and IL-1b release downstream of the NLRP3 activator niger-
icin (Figure 7C). At the same time, hyperkalemic extracellular
conditions completely abrogated caspase-1 activation upon
birinapant and Vio A treatment. In contrast, increased extracel-
lular potassium levels had no impact on caspase-8 processing
and only a slight effect on IL-1b release after birinapant and
Vio A stimulation. Next, to determine the ability of Vio A to induce
MOMP in other cell types, we usedmurine embryonic fibroblasts
(MEFs). Similar to macrophages, MEFs also require two triggers
for the induction of MOMP (White et al., 2014). In line with our
previous results, Vio A also induced MOMP in MEFs cells, albeit
with somewhat delayed kinetics, similar to the results obtained in
SVECs (Figure S7C).
Furthermore, to assess the bioactivity of Vio A in human cells
and compare the observations with the murine system, primary
monocytes were isolated from human PBMCs. To circumvent
alternative inflammasome activation (Gaidt et al., 2016), cells
were primed with Pam3CSK4 and stimulated with nigericin and
Vio A in the absence or presence of the NLRP3 inhibitor
(MCC950) (Figures 7D and 7E). As expected, nigericin led to
IL-1b and LDH secretion (Gaidt et al., 2017) (Figure 7E), which
correlated with the release of cleaved caspase-1 into the super-
natant (Figure 7D). Moreover, this release of mature IL-1b and
caspase-1 and nigericin-induced LDH release was completely
blocked by the addition of MCC950 (Figure 7E). Similar to
BMDMs, Vio A also resulted in IL-1b and LDH release in human
monocytes. However, unlike nigericin, IL-1b and LDH release
by Vio A was largely independent of NLRP3 inhibition, and this
IL-1b release correlated with caspase-8 activation (Figure 7D).
Furthermore, MCC950 blocked the cleavage of Vio A-induced
caspase-1 in monocytes, while the activity of caspase-8 and
caspase-3 was largely unaffected (Figure 7D). In line with our
findings in murine cells, this inhibition of caspase-1 activation
also had no substantial effect on IL-1b release (Figures 7A
and 7D).
In summary, our data indicate that vioprolide-induced ripopto-
some/caspase-8 activation constitutes the prime mechanism of
IL-1b maturation in the context of MOMP. Moreover, in addition
to this functionality, caspase-8 triggers a lytic cell death that re-
sults in K+ efflux and thereby secondary activation of the NLRP3
inflammasome. However, this mechanism has only a subordi-
nate role in the observed IL-1b maturation (Figure S7D).
DISCUSSION
Here, we formally define a signaling route that connects intrinsic
apoptosis to the activation of IL-1b, a gatekeeper cytokine of
inflammation. Validating hits from a small molecule screen
aimed at identifying previously uncharacterized regulators of in-
flammasome activation, we identified vioprolides as a class of
compounds that can trigger IL-1b maturation in macrophages.
This functionality turned out to be largely independent of inflam-
masome activation. Instead, vioprolide-dependent IL-1b matu-
ration was found to be connected to its capacity to trigger2364 Cell Reports 25, 2354–2368, November 27, 2018intrinsic apoptosis. As such, vioprolides initiate MOMP in a
BAX/BAK-dependent manner via two distinct functionalities:
on the one hand, they act as translation inhibitors, which result
in a decrease in MCL-1 levels, a pivotal pro-survival BCL2 family
protein; on the other hand, they confer a second signal through
BCL2 inhibition to initiate BAX/BAK-dependent MOMP. In
keeping with this mode of action, we could mimic all viopro-
lide-dependent effects by treating macrophages with a combi-
nation of a translational inhibitor to decrease MCL-1 levels
and the compound ABT-737 to trigger BAX/BAK activation.
While the induction of MOMP results in the activation of intrinsic
apoptosis via caspase-9, it also initiates in IAP depletion.
Consequently, depletion of IAPs leads to a caspase-8-contain-
ing ripoptosome complex that directly matures IL-1b. Cas-
pase-8 activity also amplifies intrinsic apoptosis, most probably
via BID cleavage. Of note, at later time points, vioprolides also
induced cell death and IL-1b release independently of NLRP3
in Bax//Bak1/ cells (data not shown). Nevertheless, this
BAX/BAK-independent cell death also resulted in IAP depletion
and subsequent caspase-8-dependent IL-1b maturation. As a
consequence of these processes, plasma membrane integrity
is breached, additionally resulting in caspase-8 dependent
and -independent K+ efflux, leading to NLRP3 activation. How-
ever, it should be noted that under these conditions, NLRP3
activity only plays a minor role in IL-1b maturation and cell
death. In summary, using genetic and biochemical tools, we
formally establish MOMP as a pro-inflammatory process in
macrophages, with the ripoptosome complex functioning as
its central molecular switch.
The Inflammasome Plays a Subordinate Role in MOMP-
Triggered Inflammation
While previous studies have implied mitochondrial perturbation
in the context of inflammasome-driven IL-1b maturation, these
reports established a connection between classical NLRP3 stim-
uli and MOMP downstream of K+ efflux (Iyer et al., 2013; Shi-
mada et al., 2012). Using genetic loss-of-functions approaches,
we can clearly show that MOMP is dispensable for this route of
NLRP3 activation. Nevertheless, dissecting intrinsic apoptosis
induction upstream of MOMP, we can establish MOMP as a
distinctive signal that leads to the release of bioactive IL-1b,
although in a different context. In fact, in this response pathway
it is specifically the activity of the ripoptosome/caspase-8 com-
plex and not of the NLRP3 inflammasome that governs IL-1b
maturation. This is intriguing in that NLRP3 activity is tightly con-
nected to cell damage, sensing K+ efflux as a proxy ofmembrane
integrity (Gaidt and Hornung, 2018). We also observe K+ efflux-
dependent NLRP3 inflammasome activation as a consequence
of MOMP, but this is a late event that is governed by the loss
of membrane integrity downstream of apoptotic caspase activa-
tion (McCarthy and Cotter, 1997). In agreement with this late
engagement of the inflammasome pathway, GSDMD deficiency
could not rescue the loss of membrane integrity that was
observed downstream of MOMP. Given that the kinetics of in-
flammasome activation normally supersede apoptotic signaling
cascades in regard to determining the cell fate, these results un-
derscore the unique functionality of apoptosis in maintaining
membrane integrity.
Intrinsic Apoptosis Is Not a Silent Cell Death Program in
Myeloid Cells
In light of the important functions of apoptosis during develop-
ment and tissue homeostasis, this programmed cell death has
been long considered to be immunologically silent. This is
achieved by complex communication between apoptotic cells
and surrounding phagocytes that leads to rapid uptake and
clearance of the apoptotic content. During this process, the
plasma membrane is considered to be intact, enabling seques-
tration of putative DAMP molecules within apoptotic bodies to
prevent inflammation (Poon et al., 2014). In fact, apoptotic path-
ways display even anti-inflammatory (inflammation-suppressive)
features: efferocytosis is known to induce an anti-inflammatory
state in the respective phagocyte (Poon et al., 2014), whereas
the apoptotic death actively avoids the initiation of cell-intrinsic
pro-inflammatory program (e.g., NF-kB, cGAS-STING [stimu-
lator of interferon genes protein]) activation during perturbed
mitochondrial integrity (Giampazolias et al., 2017; Rongvaux
et al., 2014; White et al., 2014), or NF-kB activation by several
death ligands, including TNF-related apoptosis-inducing ligand
(TRAIL), FAS, or TNF (Park et al., 2005).
Nonetheless, a number of reports have indicated apoptosis as
a potent mediator of inflammation in in vitro as well as in vivo set-
tings (Bossaller et al., 2012; Faouzi et al., 2001). Although the
detailed molecular mechanisms of apoptosis-mediated inflam-
mation have remained elusive, the present study provides
conclusive evidence that intrinsic apoptosis triggers pro-inflam-
matory signaling through the maturation of IL-1b. Although
initially guided by the characterization of vioprolides, which can
trigger intrinsic apoptosis in macrophages via a 2-fold function-
ality, the inflammatory consequences of vioprolide-mediated
apoptosis are generally applicable to apoptotic cell death pro-
grams. As such, treating macrophages with cycloheximide and
ABT-737 resulted in the same response pattern. Furthermore,
it is presumable that cytokine release is not the only pro-inflam-
matory aspect of apoptotic cell death. It has been shown that
other cell types, such as epithelial cells or keratinocytes, are
capable of ripoptosome formation (Feoktistova et al., 2011;
Tenev et al., 2011). Given that these cells do not express IL-1b,
it will be of interest to determine whether and how the MOMP-
apoptotic factors-IAP depletion-ripotosome-caspase-8 pathway
triggers inflammation here.
The Ripoptosome Functions as an Innate Sensor
IL-1bmaturation by inflammasomes is an important aspect of the
antimicrobial immune defense, with inflammasome receptors
serving as ‘‘non-self-recognition units.’’ While certain inflamma-
some receptors do not participate in direct pattern recognition,
their domain architecture and signaling cascades are shared
with bona fide pattern recognition receptors (PRRs). An intriguing
finding of our work is that there is no PRR or PRR-like molecule
required for IL-1b maturation during intrinsic apoptosis. Instead,
it is the ripoptosome complex that functions as an indirect sensor
of organelle integrity (MOMP), with IAP depletion as its activating
signal. Of note, IAPdepletion coincidingwith caspase-8 activation
was not only seen for the early BAX/BAK-dependent pathway of
vioprolide-dependent IL-1b maturation but also observed for the
late, BAX/BAK-independent pathway. These observations furtherstrengthen the role of the ripoptosome/caspase-8 complex in
damage sensing. This mode of action is in keeping with the
concept of effector-triggered immunity (ETI), inwhich cells identify
pathogen-driven disturbances rather than pathogen-derived mo-
lecular patterns (Stuart et al., 2013). From the host perspective,
this mode of recognition bears the advantage of being indepen-
dent of a specific microbial pattern, which may evade recognition
under selection pressure. In this context, it is intriguing that IAP
molecules are involved in two distinct signaling capacities, both
serving the induction of pro-inflammatory responses. On the one
hand, IAP molecules play crucial roles in propagating pro-inflam-
matory signal transduction cascades downstream of PRR and
cytokine receptors (Darding and Meier, 2012). On the other
hand, their presence is critically required to prevent the formation
of a ripoptosome/caspase-8 complex that can mature the highly
pro-inflammatory cytokine IL-1b. These characteristics enable
IAPmolecules to serve as the rheostat of two independent pro-in-
flammatory signaling cascades.
While our study does not formally establish the ripoptosome
as a pathogen-driven ETI sensor, it is noteworthy that ripopto-
some-dependent ETI seems not to be limited to MOMP-medi-
ated activation. To this end, the Yersinia pestis effector YopJ
has been reported to induce caspase-8-dependent IL-1b matu-
ration in a BAX/BAK-independent fashion (Weng et al., 2014;
Zheng et al., 2012). Formally establishing the ripoptosome as
an ETI sensor under these pathogenic settings could provide
further insights into IL-1b maturation pathways and ETI in the
mammalian system in general.STAR+METHODS
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Primer: Hprt Forward: CTGGTGAAAAGGACCTCTCG Bieging et al., 2009 NA
Primer: Hprt Reverse: TGAAGTACTCATTATAGTCAAGGGCA Bieging et al., 2009 NA
Primer Mcl1 Forward: TGTAAGGACGAAACGGGACT Austin and Cook, 2005 NA
Primer Mcl1 Reverse: AAAGCCAGCAGCACATTTCT Austin and Cook, 2005 NA
Recombinant DNA
Hemoglobin subunit beta-pT7CFE1 This study NA
Software and Algorithms
GraphPad Prism 5 GraphPad NACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Veit
Hornung (hornung@genzentrum.lmu.de).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All described mouse lines were housed under specific pathogen-free conditions. Animal housing and handling was conducted in
accordance with the Principles of Laboratory Animal Care guidelines approved by the Local Animal Care Commission of North
Rhine-Westphalia and supervised by Institutional Animal Care and Use Committee (IACUC) of the Medical Faculty, University of
Bonn (HET, House of Experimental Therapy, University Hospital, University of Bonn). Mice were euthanized according to the FELASA
guidelines by cervical dislocation. The gender of the individual mice was not documented for this study.
Preparation of murine bone marrow derived macrophages (BMDMs)
BMDMs were derived from bone marrow (BM) of 8-12 weeks old C57BL/6 mice. Nlrp3/ (Mariathasan et al., 2006), Pycard/ (Ma-
riathasan et al., 2004) were kindly provided by Vishva Dixit (Genentech, USA), Casp1/11/ (Kuida et al., 1995) were from Richard A.
Flavell (Yale University, USA), bonemarrow ofCasp8//Ripk3/ (Kaiser et al., 2011),Ripk3/ (Newton et al., 2004) were a gift frome2 Cell Reports 25, 2354–2368.e1–e5, November 27, 2018
Egil Lien (UMASSMedical School). OXP-BCL2mice (Knittel et al., 2016) were fromHamid Kashkar (University of Cologne, Germany).
Bone marrow of Bax//Bak1/ mice (Vince et al., 2012) was kindly provided by James Vince (WEHI, Australia), Gsdmd/
(Schneider et al., 2017) from Petr Broz (University of Lausanne, Switzerland). Bone marrow cells were filtered and subjected to eryth-
rocyte lysis (BD Pharm lyse). For the derivation of macrophages, bone marrow cells were supplemented with 30% L929 supernatant
for 6-7 days. Cells were plated one night before the stimulation.
Isolation of human primary cells
PBMCs were isolated from heparinized blood or buffy coats from informed, consenting, and healthy volunteers according to the
principles of the Declaration of Helsinki, approved by the responsible ethics committee (Ethics committee of the Medical Faculty,
University of Bonn). Monocytes were isolated using CD14 MACS microbeads (Miltenyi Biotec) according to the manufacturer’s
protocol.
Primary cell culture
Human PBMCs and primary monocytes were cultured in RPMI medium 1640 supplemented with L-glutamine, sodium pyruvate,
10% (v/v) heat inactivated FCS and 100U/ml Penicillin-Streptomycin (all Life Technologies). Human PBMCs and monocytes (both
at 1x105/well) were plated in 96 flat-well plate 2 h before the experiment. For Western Blot preparation, human monocytes
(3x105/well) were seeded in 96 flat bottom plates with 3% FCS containing RPMI medium and samples from 5 wells were combined
for each condition. All BMDMs were cultivated in DMEM supplemented with L-glutamine with same additive as above. BMDMs
cells (1x106) were plated either in 12 well plates or 1x105 cells in 96 flat bottom plates/well. Primary MEFs were cultured in DMEM
medium with 10% (v/v) heat inactivated FCS and 100U/ml Penicillin-Streptomycin along with 1% non-essential amino acids
(all Life Technologies) and 100 mM b-Mercaptoethanol (Sigma Aldrich).
Cell lines
SVEC cells were cultured in DMEM medium containing 10% FCS and 2 mM Glutamine. HeLa S3 cells were grown to a density of
3.0–5.5 3 105 in SMEM (Sigma), supplemented with 10% FCS (GIBCO), Penicillin (100 U/ml) and 1x GlutaMAX (GIBCO) at 37C,
5% CO2 using a spinner flask (40 rpm).
METHODS DETAILS
Cell stimulation
If not indicated otherwise, BMDMs cells were primed with 200 ng/ml ultrapure E.coli LPS (Invivogen) for 4 h. For dsDNA stimulation,
1 mg/ml of pBlueScript Plasmid DNA, isolated from E. coli with a Maxiprep Kit (Invitrogen) were complexed to Lipofectamine 2000
(Life Technologies) according to manufacturer’s protocol, and cells were stimulated with the mix for 8 h. If not stated otherwise,
Vio A, B, C and D (purified as previously described (Yan et al., 2018)) were used at 20 mM, nigericin (Sigma-Aldrich), birinapant
(Biovision) and staurosporine (Santa Cruz) were added at final 6.5 mM, 20 mM and 1 mM concentrations, respectively, for 8 h. Inhib-
itors: MG-132 (Selleck chemicals), cycloheximide (Carl Roth), MCC950 (Tocris bioscience) and ABT-737 (Santa cruz) were used
at 12.5 mM, 1mg/ml, 10 mM and 1 mM, respectively. In mito-priming assay, cells were stimulated with 1 mM concentration of either
ABT-199 (BCL2i) or A-1155463 (BCL-XLi) or S63845 (MCL-1i) specific inhibitor for BCL2, BCL-XL and MCL-1, respectively or with
mentioned vioprolides concentrations. For high extracellular K+ concentration, cells were incubated in medium that was diluted
with 150 mM KCl (Roth) in sterile water to contain indicated concentrations of K+ in the medium (Gaidt et al., 2016).
Immunoblotting, LDH and ELISA assay
BMDMs cells were plated in 12 well plates for immunoblots. Next day, cells were stimulated in 1% FCS medium for indicated times.
Supernatants were taken separately from 12 well plate for IL-1b ELISA (50 ml) (BD bioscience) and LDH (40 ml) (Thermo scientific),
performed according to manufacturer’s instructions. LDH is depicted as a percentage relative to direct cell lysis It was calculated
as LDH release (%) = 100 * (measurement – unstimulated control)/ (direct lysis control – unstimulated control). Remaining superna-
tants were precipitated and resuspended in 1X SDS laemmli buffer (Jakobs et al., 2013). Cells were lysed directly on plates in 1X SDS
laemmli buffer. Samples were heated at 95Cwith 1100 rpm and loaded on SDS-PAGE gel (5% stacking gel and 12% separating gel;
BioRad). Afterward, proteins were transferred on nitrocellulose membrane (Amersham, GE healthcare) for 1 h. Membranes were
blocked for another 60 min in 3% milk in PBST (PBS containing 0.05% Tween 20). All primary antibodies were incubated at least
overnight in 1%milk in PBST at 4C. Next day, membranes were incubated for at least 1 h in secondary antibody and washed gently
in PBST buffer for further 30-60min. Chemiluminescent signal was recordedwith CCD camera in Fusion SL (PEQLAB). In some blots,
whole image was contrast-enhanced in a linear fashion.
Quantitative PCR
BMDMs (7x105) were plated in 12 well plates and stimulated for 4 h. Cells were lysed in RLT buffer. Total RNA was isolated using
RNeasy mini kit from QIAGEN (74106) followed by DNase I (Thermo Fisher Scientific, EN0525) treatment. Afterward, cDNA was pre-
pared using RevertAid RT (Thermo, EP0441) using supplier’s instructions. Real time PCR was performed using Fast SYBR greenCell Reports 25, 2354–2368.e1–e5, November 27, 2018 e3
(Thermo Fisher Scientific, 4385618) according tomanufacturer’s instructions.Hprt (Fwd primer: 50-CTGGTGAAAAGGACCTCTCG-30
and Rev primer: 50-TGAAGTACTCATTATAGTCAAGGGCA-30) (Bieging et al., 2009) was used as endogenous control. Expression of
Mcl1 was measured using Fwd primer: 50-TGTAAGGACGAAACGGGACT-30 and Rev primer: 50-AAAGCCAGCAGCACATTTCT-30
(Austin and Cook, 2005).
Cytoplasmic extraction of BMDMs
BMDMs were plated at 6-8x106 cells per well in 6 well plate. Medium was replaced with fresh pre-warm medium with 1% FCS. After
stimulation, medium was removed and cells were washed with PBS. Cells were lysed with buffer A (250 mM sucrose, 10 mMHEPES
pH 7.8, 10mMKCl, 2mMMgCl2, 0.1 mMEGTA, 1mMDTT, 0.1%NP-40, complete protease inhibitor cocktail and 0.5mMPMSF). To
remove cell nuclei, lysates were centrifuged at 700 g for 15min. Supernatants were taken and centrifuged again for 20min at 12000 g
(modified from (Park et al., 2013)). Resulting supernatants were used as cytoplasmic fraction and protein concentrations were
measured with BCA kit (Pierce protein assay kit). Measured samples were mixed with 6X SDS laemmli buffer before running on
SDS-PAGE gels. Beta actin was used as loading control. COXIV was used as control for mitochondrial contamination in cytoplasmic
samples.
DNA laddering assay
BMDMs (2x106) were plated in 12 well-plate for each condition. DNA laddering assay was performed as described previously with
some changes (Kralj et al., 2003). Briefly, after stimulation cells were washed with PBS and lysed in 200 ml of lysis buffer (1%NP-40 in
20 mM EDTA, 50 mM Tris-HCl, pH 7.5). samples were centrifuged at 3000 rpm for 5 min and supernatants were collected. SDS (1%)
and RNase A (5 mg/ml) were added for 1 h at 56C. it was followed proteinase K (2.5 mg/ml) treatment for 1 at 37C. Afterward,
½ volume of ammonium acetate (stock 10M), 2 volume of ice cold ethanol and small amount of glycogen were added to the samples.
It was followed by incubated at80C overnight for precipitation. Next day, after centrifugation (14000 rpm) for 40 min at 4C, pellets
were washed with 70% ethanol and dissolved in 20 ml of water. Equal amounts of DNA were loaded for each condition on a 2%
agarose gel.
Plasmid preparation for hemoglobin subunit beta (HBB)
The HBB construct was cloned into the pT7CFE1 backbone as described previously (Matheisl et al., 2015). Sequence of mRNA
construct:
ATGgcccaccaccaccaccaccacctggccaccacccatatgCTGGAAGTGCTGTTTCAGGGCCCGtacccatacgatgttccagattacgctGTGCATC
TGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGATGAAGTTGGTGGTGAGGCCCTGGGCAG
GCTGCTGGTGGTCTACCCTTGGACCCAGAGGTTCTTTGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTGTTATGGGCAACCC
TAAGGTGAAGGCTCATGGCAAGAAAGTGCTCGGTGCCTTTAGTGATGGCCTGGCTCACCTGGACAACCTCAAGGGCACCTTTG
CCACACTGAGTGAGCTGCACTGTGACAAGCTGCACGTGGATCCTGAGAACTTCAGGCTCCTGGGCAACGTGCTGGTCTGTGTG
CTGGCCCATCACTTTGGCAAAGAATTCACCCCACCAGTGCAGGCTGCCTATCAGAAAGTGGTGGCTGGTGTGGCTAATGCCCT
GGCCCACAAGTATCACTAA
Human in vitro translation extract
As described previously (Matheisl et al., 2015), The translation extract was prepared using HeLa S3 cells. In brief, HeLa S3 cells were
harvested (2 min, 650 g) and the pellet was washed 3 times with washing Buffer (35 mM HEPES/KOH pH 7.5, 140 mM NaCl, 11 mM
Glucose) (1 min, 650 g) and 1x with extraction Buffer (20 mMHEPES/KOH pH 7.5/4C, 45mMKOAc, 45 mMKCl, 1.8 mMMg(OAc)2,
1 mM DTT). Next, the cell pellet was resuspended in extraction Buffer (1.2 3 109 cells/ml) and disrupted by nitrogen pressure
(300 psi, 30 min, 4C) in a cell disruption vessel (Parr Instrument). Next, the lysate wasmixed with 1/29 volume high potassium buffer
(20 mM HEPES/KOH pH 7.5/4C, 945 mM KOAc, 945 mM KCl, 1.8 mM Mg(OAc)2, 1 mM DTT) and incubated at 4C for 5 min,
followed by brief centrifugation step (20 s, 14 000 rpm, 4C). Aliquots of the resulting supernatant were frozen in liquid nitrogen
and stored at 80C.
In vitro transcription
In vitro transcription was performed as previously with someminor changes (Matheisl et al., 2015). Plasmid was linearized with SpeI-
HF (NEB) in CutSmart (NEB) buffer at 37C overnight and purified by QIAquick PCR purification kit (QIAGEN) before in vitro transcrip-
tion (tc) to ensure the right length of themRNA product. The final mRNA construct encoded a CrPV IGR IRES sequence for translation
initiation, an N-terminal HA- and (His)6-tag, the human HBB sequence and a polyA-tail. The reaction was performed in tc buffer
(40 mM Tris/HCl pH 7.9/4C, 26 mM MgCl2, 0.01% Triton X-100, 2.5 mM Spermidine, 5 mM DTT, 6.25 mM ATP, 6.25 mM CTP,
6.25 mM GTP, 6.25 mM UTP, 0.2 U/ml RNasin (Ambion)) with home-made T7 RNA polymerase and 1.5 mg linearized plasmid per
100 mL reaction was used. The tc reaction was incubated for 4 h at 37C. Additional amount of T7 RNA polymerase was added during
incubation. The resulting mRNA was purified by LiCl precipitation method and stored at 80C.e4 Cell Reports 25, 2354–2368.e1–e5, November 27, 2018
In vitro translation
In vitro translation (tl) was performed in tl buffer (14 mM HEPES/KOH pH 7.5/4C, 135 mM KOAc, 20.1 mM KCl, 31 mM Mg(OAc)2,
2 mM DTT, 0.25 mM GTP, 1.56 mM ATP, 16 mM Creatine Phosphate (Roche), 0.45 mg/ml Creatine Kinase (Roche), 50 mg/ml yeast
tRNA, 0.4 mM Spermidine) with 50% (v/v) extract. This mixture was supplemented with 0.12 mM amino-acid mixture, complete
(Promega) and 0.885 U/ml RNasin (Ambion). 1 mg mRNA/12 mL translation reactions were added before incubation for 40 min at
30C (modified from (Matheisl et al., 2015)). Reactions were terminated using 1X SDS laemmli buffer and samples were heated
for 5 min at 65C before loading of SDS-PAGE gel. Samples were probed using anti-HA antibody (H6908) from Sigma.
Mito-priming Assay
Mitoprimed SVEC cells (Lopez et al., 2016) expressing eGFP-tBID 2A Bcl-2, eGFP-tBID 2A Bcl-XL or eGFP-tBID 2A Mcl-1 were
seeded in 24 well plates (3x104 cells/well) overnight. The following day, cells were treated in the presence of 30 nM Sytox Green
(Life Technologies) together with the indicated compounds and imaged using an Incucyte FLR instrument (Essen Bioscience).
Four images per well were acquired every hour, and the number of Sytox green positive cells per mm2 were determined. Results
were normalized to the initial confluency of each well.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
If not stated otherwise, data are presented as mean values of the indicated number of independently conducted experiments,
whereas the error bars represent the standard error of mean (SEM). If indicated, data were analyzed for statistically significant dif-
ferences using Two-way ANOVA or One-way ANOVA using Bonferoni’s correction for multiple testing if multiple conditions or exper-
imental groups were to be compared. Gaussian distribution and sphericity of datasets were assumed. For qPCR, logarithmic values
were used to obtain a normal distribution before performing statistics. Time course experiments in mito-primed cells were evaluated
using the Kruskal-Wallis H test (non-parametric one-way ANOVA) and posthoc analysis with Dunn’s multiple comparison test. The
statistical analysis was performed using GraphPad. ** p < 0.01, * p < 0.05, ns = not significant.
DATA AND SOFTWARE AVAILABILITY
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